Atypical hemolytic uremic syndrome - PDFSEARCH.IO - Document Search Engine

Atypical hemolytic uremic syndrome
Results: 14

#	Item
11	Stakeholder meeting statement Pharmaceutical Benefits Scheme listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome A stakeholder meeting was held on 24 June 2014 to discuss the Pharmaceutical Benefi Add to Reading List Source URL: www.pbs.gov.au Language: English - Date: 2014-10-01 21:51:53 Organ failure Immunosuppressants Eculizumab Kidney diseases Hemolytic-uremic syndrome Chronic kidney disease Dialysis Pharmaceutical Benefits Scheme Kidney transplantation Medicine Health Nephrology
12	Stakeholder meeting statement Pharmaceutical Benefits Scheme listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome A stakeholder meeting was held on 24 June 2014 to discuss the Pharmaceutical Benefit Add to Reading List Source URL: www.pbs.gov.au Language: English - Date: 2014-10-01 21:51:53 Organ failure Immunosuppressants Eculizumab Kidney diseases Hemolytic-uremic syndrome Chronic kidney disease Dialysis Pharmaceutical Benefits Scheme Kidney transplantation Medicine Health Nephrology
13	The Clinical Assessment Tool An important tool that helps you and your patients monitor aHUS As you know, atypical Hemolytic Uremic Syndrome (aHUS) is a serious, chronic, devastating disease that requires ongoing monito Add to Reading List Source URL: www.ahussource.com Language: English - Date: 2013-04-05 22:20:38
14	CASE REPORT Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479 Preeti Chaudhary1, Mehmet Hepgur1, Sarmen Sarkissian2, Richard J.H. Smith3, Ilene C. Weitz1 1 Add to Reading List Source URL: www.ncbi.nlm.nih.gov Language: English Biology Factor H Hemolytic-uremic syndrome Eculizumab Complement factor I Complement component 3 Alternative complement pathway Alexion Pharmaceuticals CFHR1 Complement system Anatomy Immune system

UPDATE